Semaglutide (20mg Vial) Dosage Protocol

Supplies Needed

Plan based on an 8–20 week weekly titration protocol.

• Peptide Vials (Semaglutide, 20 mg each):
  • 8 weeks ≈ 1 vial (3 mg total used)
  • 12 weeks ≈ 1 vial (7 mg total used)
  • 16 weeks ≈ 1 vial (13.8 mg total used)
  • 20 weeks ≈ 2 vials (23.4 mg total used with maintenance dosing)
• Insulin Syringes (U-100):
  • Per week: 1 syringe
  • 8 weeks: 8 syringes
  • 12 weeks: 12 syringes
  • 16 weeks: 16 syringes
  • 20 weeks: 20 syringes
• Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
  • 8 weeks (1 vial): 3 mL → 1 × 10 mL bottle
  • 12 weeks (1 vial): 3 mL → 1 × 10 mL bottle
  • 16 weeks (1 vial): 3 mL → 1 × 10 mL bottle
  • 20 weeks (2 vials): 6 mL → 1 × 10 mL bottle

  Note: Use bacteriostatic water within 28 days after opening^[9].

• Alcohol Swabs: One for the vial stopper + one for the injection site each week.
  • Per week: 2 swabs
  • 8 weeks: 16 swabs
  • 12 weeks: 24 swabs
  • 16 weeks: 32 swabs
  • 20 weeks: 40 swabs → recommend 1 × 100-count box

View Supplier

View Supplier

View Supplier

View Supplier

Important Notes

Practical considerations for consistency and safety.

• Use new sterile insulin syringes for each injection; dispose in a proper sharps container^[11].
• Rotate injection sites systematically (abdomen, thighs, upper arms) to reduce local irritation and avoid lipohypertrophy^[10].
• Inject slowly and steadily; wait a few seconds before withdrawing the needle to ensure complete delivery.
• Administer on the same day each week for consistency; if a dose is missed, take it as soon as possible within 5 days of the missed dose^[4].
• GLP-1 receptor agonists may cause gastrointestinal side effects (nausea, vomiting); gradual dose escalation helps minimize these effects^[1][3].
• The 20 mg vial size provides excellent economy for weekly dosing, with a single vial lasting 16+ weeks through the escalation phase.

How This Works

Semaglutide is a GLP-1 receptor agonist with 94% sequence homology to native human GLP-1^[4]. It promotes weight loss through multiple mechanisms: reducing appetite and food intake via central nervous system effects, slowing gastric emptying, and improving glycemic control through glucose-dependent insulin secretion^[1][3]. The extended half-life of approximately 7 days is due to albumin binding and resistance to DPP-4 degradation, enabling convenient once-weekly dosing^[1]. Clinical trials have demonstrated significant weight loss (mean 10–15% body weight reduction) in individuals with obesity when combined with lifestyle interventions^[1][5]. The weekly 2.4 mg maintenance dose is FDA-approved for chronic weight management and represents the standard clinical approach^[3][4].

Potential Benefits & Side Effects

Observations from clinical literature and regulatory approvals^[1][3][5].

Potential Benefits:

• Significant weight loss (mean 10–15% body weight reduction in clinical trials at 2.4 mg weekly dose) when combined with lifestyle modifications^[1][5].
• Improved glycemic control through enhanced glucose-dependent insulin secretion and reduced glucagon secretion^[3].
• Reduced appetite and food intake via central nervous system GLP-1 receptor activation^[1].
• Cardiovascular benefits demonstrated in outcome trials, including reduced risk of major adverse cardiovascular events^[6].
• Convenient once-weekly dosing improves adherence compared to daily regimens^[1].

Potential Side Effects:

• Gastrointestinal effects (most common): nausea, vomiting, diarrhea, constipation, abdominal pain—typically mild to moderate and decreasing with gradual dose escalation^[1][3].
• Injection-site reactions: redness, swelling, or irritation (generally mild and transient)^[11].
• Hypoglycemia risk (when combined with insulin or sulfonylureas)—less common with semaglutide monotherapy due to glucose-dependent mechanism^[3].
• Rare serious adverse events: pancreatitis, gallbladder disease, acute kidney injury; thyroid C-cell tumors observed in rodent studies (relevance to humans uncertain)^[4].

Lifestyle Factors

Complementary strategies for optimal outcomes with GLP-1 therapy^[1][5].

• Maintain a balanced, calorie-controlled diet with adequate protein intake (1.2–1.6 g/kg body weight) to preserve lean muscle mass during weight loss.
• Combine regular physical activity including both resistance training (2–3 days per week) and aerobic exercise (150+ minutes per week) to reinforce metabolic adaptations and improve body composition.
• Prioritize consistent sleep (7–9 hours nightly) and effective stress management to support adherence and metabolic health.
• Stay well-hydrated (8–10 glasses of water daily), especially if experiencing gastrointestinal side effects.
• Monitor progress through regular weigh-ins, body measurements, photos, and consultation with healthcare providers.
• Consider working with a registered dietitian for personalized nutrition guidance during weight loss.

Injection Technique

General subcutaneous injection guidance from clinical best-practice resources^[10][11][12].

• Clean the vial stopper and chosen skin site with separate alcohol swabs; allow both to dry completely before proceeding^[11].
• Pinch a fold of skin between your fingers; insert the needle at a 45–90° angle into the subcutaneous tissue (fatty layer, not muscle)^[10][12].
• Do not aspirate (pull back the plunger) when giving a subcutaneous injection^[10].
• Inject the solution slowly and steadily; wait at least 6 seconds after injection before withdrawing the needle to ensure complete delivery and minimize leakage.
• Withdraw the needle and apply light pressure with a clean swab; avoid rubbing vigorously.
• Rotate injection sites systematically (abdomen, thighs, upper arms) with each weekly injection to prevent lipohypertrophy and maintain consistent absorption^[11]. The abdomen is the preferred site for most consistent absorption.
• Dispose of used syringes and needles immediately in a proper FDA-approved sharps container^[12].